Antipsychotic Discontinuation and Re-initiation in Pregnant Women With Schizophrenia: A Retrospective Cohort Study From South Korea

韩国一项回顾性队列研究:妊娠期精神分裂症患者抗精神病药物停用与再启用情况

阅读:1

Abstract

BACKGROUND AND HYPOTHESIS: Pregnant women with schizophrenia are more likely to discontinue treatment, which could trigger a relapse of symptoms. However, data on patterns and risk factors related to antipsychotic discontinuation and re-initiation in Asian pregnant women are insufficient. STUDY DESIGN: We conducted a retrospective cohort study using a nationwide Korean database. The pregnancy group included women who had received antipsychotics before pregnancy and was matched 1:2 with a non-pregnancy group. Using Kaplan-Meier curves, we assessed discontinuation patterns during pregnancy and re-initiation patterns among those who discontinued treatment within the first trimester. A Cox proportional hazards regression analysis was used to examine factors associated with first-trimester discontinuation and re-initiation among those who discontinued during this period. STUDY RESULTS: Pregnant women (n = 2066) had a significantly higher risk of discontinuation than did non-pregnant women (adjusted hazard ratio 3.09; 95% confidence interval 2.85-3.34). Within the first trimester, 67.5% of pregnant women (n = 1394) discontinued antipsychotic use. Women aged 25-29 years were more likely to discontinue (1.25; 1.07-1.47). Among first-trimester discontinuers, 35.2% (n = 491) re-initiated treatment before delivery. A longer duration of antipsychotic use (1.60; 1.06-2.42) and higher daily doses (2.47; 1.76-3.45) were associated with re-initiation of antipsychotics. CONCLUSIONS: We revealed that most pregnant women discontinued schizophrenia treatment, but those using higher cumulative doses had a higher likelihood of re-initiation. Our findings imply that treatment decisions for pregnant women should consider various clinical factors, including the history of prescriptions and obstetric characteristics. Moreover, these patients require close monitoring after discontinuation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。